GLP-1s Go Mainstream, Longevity Claims Get a Reality Check

eMed, the telehealth platform Tom Brady is fronting, has reached a $2 billion valuation on the strength of employer-sponsored GLP-1 access. CEO Yaccarino says only one in five employers currently cover the drugs as a benefit — a number she expects to climb fast. For advisors booking longevity and medical-wellness programs, that trajectory matters more than the valuation headline: more clients will arrive at SHA Wellness, Lanserhof, Clinique La Prairie or Mayrlife already on GLP-1 therapy, not seeking it. Expect these operators to formalize pre-arrival medical screening, adjust nutrition protocols around GLP-1 side effects, and reconsider program length for users managing the drugs long-term. Corporate wellness-retreat buyers, meanwhile, may start treating GLP-1-inclusive programming as a benefit differentiator alongside the retreat itself — worth raising proactively with corporate clients before they ask.

Industry critics at BeautyMatter and Longevity Technology are pushing back on the rush to slap "longevity" and "cellular health" language on treatments with little clinical evidence behind them, as skin longevity becomes one of this year's dominant wellness-marketing trends. The warning lands squarely on advisors' desks: as destination spas and longevity clinics roll out skin- and cellular-longevity add-ons alongside their core medical programming, the same scrutiny applies. Before positioning any such add-on as medical-grade to a client, ask the supplier what clinical substantiation actually backs the claim — not just the marketing copy. This is a due-diligence habit worth building into supplier vetting now, particularly for programs adjacent to established longevity players where a loosely substantiated add-on could undercut trust in the core offering.

A documented consumer trend — "I trust my own body" — is surfacing real resistance to constant biometric tracking, per Global Wellness Institute coverage this month. For a segment that has spent years selling diagnostics dashboards and wearable-integrated longevity programs, this is a signal worth testing rather than ignoring. Properties built around intuition and disconnection, such as Vana or Kamalaya, may find a receptive audience in clients fatigued by self-quantification. Advisors marketing data-heavy longevity diagnostics packages should have a low-tech counter-narrative ready for clients who ask for less monitoring, not more — framing a retreat's value around rest and disconnection rather than another stream of biometric output.